burn30 glp-1 GLP1+ Nutrex Nutrex GLP1+ Control

Prior efforts to treat obesity demonstrate that sustained weight reduction is a Herculean task--thus it may be the case that GLP-1 agents will need to be administered chronically to sustain anti-obesity benefits

In the STEP1 trial, weekly semaglutide 2.4 mg caused an average ~15% body weight reduction over 68 weeks, vs ~2.5% with placebonews.cornell.edunews.cornell.edu

Equally important is the urgent need to design societal health responses able to better identify, prevent and manage the disease (WHO 2023)

Bile acids have demonstrated effects on stimulating GLP-1 secretion from L-cells by acting through a specific G protein-coupled receptor (TGR5) versus their other common receptor a nuclear transcription factor, FXR (115)

In the management of diabetic retinopathy (DR), anti-vascular endothelial growth factor (anti-VEGF) agents have emerged as first-line therapeutic interventions [11]

Tirzepatide, the active ingredient in Mounjaro and Zepbound, is now being studied for treatment of kidney disease